Literature DB >> 21635204

Telomere length in myelodysplastic syndromes.

Dana E Rollison1, P K Epling-Burnette, Jong Y Park, Ji-Hyun Lee, Hyun Park, Kristen Jonathan, Ashley L Cole, Jeffrey S Painter, Mayenha Guerrier, Johana Meléndez-Santiago, William Fulp, Rami Komrokji, Jeffrey Lancet, Alan F List.   

Abstract

The relationship between telomere length (TL) and predisposition to myelodysplastic syndromes (MDS) remains unclear. We compared peripheral blood leukocyte (PBL) TL among cases of histologically confirmed MDS (n = 65) who were treatment-naive with no prior cancer history to age-matched controls (n = 63). Relative TL was measured in PBLs and saliva by quantitative polymerase chain reaction (PCR) and in CD15+ and CD19+ cells by flow cytometry-fluorescence in situ hybridization (flow-FISH). Human telomerase reverse transcriptase gene (hTERT) mutations were assessed by PCR. After adjustment for age and sex, relative TLs were reduced in PBLs (p = 0.02), CD15+ (p = 0.01), CD19+ (p = 0.25), and saliva (p = 0.13) in MDS cases versus controls, although only the PBL and CD15+ results were statistically significant. Among MDS cases, CD15+ and CD19+ cell TLs were positively correlated (p = 0.03). PBL TL was reduced among those occupationally exposed to paints and pesticides, but was not associated with hTERT genotype. Future studies are needed to further investigate constitutional telomere attrition as a possible predisposing factor for MDS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21635204      PMCID: PMC4350661          DOI: 10.3109/10428194.2011.568648

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  38 in total

Review 1.  The extent and significance of telomere loss with age.

Authors:  Duncan M Baird; David Kipling
Journal:  Ann N Y Acad Sci       Date:  2004-06       Impact factor: 5.691

2.  Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry.

Authors:  T H Brümmendorf; T L Holyoake; N Rufer; M J Barnett; M Schulzer; C J Eaves; A C Eaves; P M Lansdorp
Journal:  Blood       Date:  2000-03-15       Impact factor: 22.113

3.  Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome.

Authors:  Hiroki Yamaguchi; Gabriela M Baerlocher; Peter M Lansdorp; Stephen J Chanock; Olga Nunez; Elaine Sloand; Neal S Young
Journal:  Blood       Date:  2003-04-03       Impact factor: 22.113

Review 4.  The World Health Organization (WHO) classification of the myeloid neoplasms.

Authors:  James W Vardiman; Nancy Lee Harris; Richard D Brunning
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

Review 5.  Telomeres and marrow failure.

Authors:  Rodrigo T Calado
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

6.  Association between telomere length in blood and mortality in people aged 60 years or older.

Authors:  Richard M Cawthon; Ken R Smith; Elizabeth O'Brien; Anna Sivatchenko; Richard A Kerber
Journal:  Lancet       Date:  2003-02-01       Impact factor: 79.321

7.  Leukocyte telomere length in a population-based case-control study of ovarian cancer: a pilot study.

Authors:  Lisa Mirabello; Montserrat Garcia-Closas; Richard Cawthon; Jolanta Lissowska; Louise A Brinton; Beata Pepłońska; Mark E Sherman; Sharon A Savage
Journal:  Cancer Causes Control       Date:  2009-09-27       Impact factor: 2.506

8.  Myeloid leukemias and myelodysplastic syndromes: chemical exposure, histologic subtype and cytogenetics in a case-control study.

Authors:  G Ciccone; D Mirabelli; A Levis; P Gavarotti; G Rege-Cambrin; L Davico; P Vineis
Journal:  Cancer Genet Cytogenet       Date:  1993-07-15

9.  Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma.

Authors:  Sujata Chakraborty; Can-Lan Sun; Liton Francisco; Melanie Sabado; Liang Li; Karen L Chang; Stephen Forman; Smita Bhatia; Ravi Bhatia
Journal:  J Clin Oncol       Date:  2009-01-05       Impact factor: 44.544

10.  Telomere dysfunction: a potential cancer predisposition factor.

Authors:  Xifeng Wu; Christopher I Amos; Yong Zhu; Hua Zhao; Barton H Grossman; Jerry W Shay; Sherry Luo; Waun Ki Hong; Margaret R Spitz
Journal:  J Natl Cancer Inst       Date:  2003-08-20       Impact factor: 13.506

View more
  20 in total

1.  I walk the line: how to tell MDS from other bone marrow failure conditions.

Authors:  Lukasz P Gondek; Amy E DeZern
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

Review 2.  Bone marrow failure and the telomeropathies.

Authors:  Danielle M Townsley; Bogdan Dumitriu; Neal S Young
Journal:  Blood       Date:  2014-09-18       Impact factor: 22.113

3.  Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion.

Authors:  Monica Cabrero; Yiting Yu; Amit Verma; Hui Yang; Simona Colla; Yu Jia; Hong Zheng; Zach Bohannan; Irene Ganan-Gomez; Andrew Futreal; Koichi Takahashi; Lynda Chin; Hagop Kantarjian; Andrea Pellagatti; Teresa Bowman; Jacqueline Boultwood; Guillermo Garcia-Manero; Yue Wei
Journal:  Br J Haematol       Date:  2015-06-24       Impact factor: 6.998

4.  A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction.

Authors:  Rami S Komrokji; Adam W Mailloux; Dung-Tsa Chen; Mikkael A Sekeres; Ronald Paquette; William J Fulp; Chiharu Sugimori; Jennifer Paleveda-Pena; Jaroslaw P Maciejewski; Alan F List; Pearlie K Epling-Burnette
Journal:  Haematologica       Date:  2014-01-31       Impact factor: 9.941

5.  Three-dimensional Nuclear Telomere Organization in Multiple Myeloma.

Authors:  Ludger Klewes; Rhea Vallente; Eric Dupas; Carolin Brand; Dietrich Grün; Amanda Guffei; Chirawadee Sathitruangsak; Julius A Awe; Alexandra Kuzyk; Daniel Lichtensztejn; Pille Tammur; Tiiu Ilus; Anu Tamm; Mari Punab; Morel Rubinger; Adebayo Olujohungbe; Sabine Mai
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

Review 6.  The challenging world of cytopenias: distinguishing myelodysplastic syndromes from other disorders of marrow failure.

Authors:  Amy E DeZern; Mikkael A Sekeres
Journal:  Oncologist       Date:  2014-06-04

7.  Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome.

Authors:  Mikko Myllymäki; Robert Redd; Christopher R Reilly; Wael Saber; Stephen R Spellman; Christopher J Gibson; Zhen-Huan Hu; Tao Wang; Esther H Orr; Jaclyn G Grenier; Maxine M Chen; David P Steensma; Corey Cutler; Immaculata De Vivo; Joseph H Antin; Donna Neuberg; Suneet Agarwal; R Coleman Lindsley
Journal:  Blood       Date:  2020-12-24       Impact factor: 22.113

Review 8.  EnvIRONmental Aspects in Myelodysplastic Syndrome.

Authors:  Verena Petzer; Igor Theurl; Günter Weiss; Dominik Wolf
Journal:  Int J Mol Sci       Date:  2021-05-14       Impact factor: 5.923

Review 9.  Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions.

Authors:  Ali N Chamseddine; Elias Jabbour; Hagop M Kantarjian; Zachary S Bohannan; Guillermo Garcia-Manero
Journal:  Curr Oncol Rep       Date:  2016-01       Impact factor: 5.945

10.  Naive T-cells in myelodysplastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiency.

Authors:  L Yang; A Mailloux; D E Rollison; J S Painter; J Maciejewski; R L Paquette; T P Loughran; K McGraw; H Makishima; R Radhakrishnan; S Wei; X Ren; R Komrokji; A F List; P K Epling-Burnette
Journal:  Leukemia       Date:  2012-10-17       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.